Treasurer Torsella Brings Shareholder Action For Gilead Oversight
Accountability needed for missteps in pandemic response at maker of COVID treatment drug
Harrisburg, PA - Pennsylvania Treasurer Joe Torsella today co-filed a shareholder proposal at Gilead, maker of remdesivir (brand name: Veklury), the only antiviral drug approved by the Food and Drug Administration to treat cases of COVID-19. The shareholder proposal, filed by Treasurer Torsella, Rhode Island Treasurer Seth Magaziner, and United Church Funds calls for an independent board chair on the Gilead board of directors. An independent board chair ensures that management of the company is held accountable for missteps and misconduct that harm patients and investors, such as Gilead’s recent unfair pricing of remdesivir, at more than 500 times its production cost according to one study, during a pandemic.